Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers including follicular lymphoma, Hodgkin's lymphoma and acute myelogenous leukemia.
via PubMed
{{chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 444509574 | ImageFile = mocetinostat.png | ImageClass = skin-invert-image | ImageSize = 200px | PIN = N-(2-Aminophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide | OtherNames = |Section1= |Section2= |Section3= }}
Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers including follicular lymphoma, Hodgkin's lymphoma and acute myelogenous leukemia.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).